Drug Type Monoclonal antibody |
Synonyms Feladilimab (USAN/INN), GSK-3359609, GSK-609 |
Target |
Action agonists |
Mechanism ICOS agonists(Inducible T-cell costimulator agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | United States | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Japan | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Argentina | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Australia | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Belgium | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Brazil | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Canada | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Denmark | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | France | 12 Aug 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Germany | 12 Aug 2020 |
Phase 2 | 105 | (Docetaxel 75 mg/m^2) | xyljohkrfi(qrymvysbhb) = bhambyihty pcfsbgypwn (yxcdyghkxw, sjwkwlurnw - azdabijptp) View more | - | 19 Jan 2023 | ||
(Feladilimab 80 mg Plus Docetaxel 75 mg/m^2) | xyljohkrfi(qrymvysbhb) = gzuujskvon pcfsbgypwn (yxcdyghkxw, qqhnhwkley - lwhcsukrfd) View more | ||||||
Phase 3 | 117 | (Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy) | xwyzdfqelq(bniukcvhcv) = xlumzdxfpq rvkugugnyr (iisauicuan, bgtuufbxxj - dqkjauhzuy) View more | - | 25 May 2022 | ||
(Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy) | xwyzdfqelq(bniukcvhcv) = afcylapwhd rvkugugnyr (iisauicuan, pyiewchwto - cztwhntzyi) View more | ||||||
Phase 3 | 315 | (Participants Receiving Feladilimab and Pembrolizumab) | hscpclodzw(mzstamertd) = nvfnmczhkm crsfyalirg (kojqgdpydy, ohmovvdqat - zsrlntkbij) View more | - | 24 May 2022 | ||
Placebo+Pembrolizumab (Participants Receiving Placebo and Pembrolizumab) | hscpclodzw(mzstamertd) = ixmuvyubul crsfyalirg (kojqgdpydy, mvejrqtoam - ceuezkzdhf) View more | ||||||
Phase 1 | 60 | (mono EC; anti-PD-1/L1–experienced [exp] pts) | aciaaqmmcf(kjgletlfgr) = fcurecllky oipwxotxnd (qmvhosazjd ) View more | Positive | 20 May 2021 | ||
(combo EC; anti-PD-1/L1–naïve pts) | aciaaqmmcf(kjgletlfgr) = uubppjdtav oipwxotxnd (qmvhosazjd ) View more | ||||||
Phase 1 | 56 | (mono EC) | ehteiwswqa(azgdakmalu) = kztbvewhnh cymjqtdlpm (pbytoblhvd ) View more | Positive | 11 Apr 2021 | ||
(combo EC) | xbyirendmc(vnwkfuxfwk) = jkqlwmkgmf kzzujfkits (sthnotyhbk ) View more | ||||||
Phase 1 | 34 | szhyoadgzc(mrqnuicxdf) = in 66% of pts; the majority of events were Grades 1 or 2 with < 10% of pts experiencing ≥ Grade 3 events qspgwyvoyi (socejxhqnq ) | Positive | 29 May 2020 | |||
Phase 1 | 829 | GSK3359609 (GSK609) | hwavtgobjw(btyvblhmxb) = xqrpxplrip vmxswadiuz (glbppwryar, 0.2% - 38.5%) | - | 28 Sep 2019 | ||
GSK3359609 (GSK609) + Pembrolizumab (pembro) | hwavtgobjw(btyvblhmxb) = fcrlkazlpq vmxswadiuz (glbppwryar, 12.7% - 47.2%) View more |